MA46673A - Utilisation de la bêta-caténine en tant que biomarqueur pour traiter des cancers à l'aide d'un anticorps anti-dkk-1 - Google Patents
Utilisation de la bêta-caténine en tant que biomarqueur pour traiter des cancers à l'aide d'un anticorps anti-dkk-1Info
- Publication number
- MA46673A MA46673A MA046673A MA46673A MA46673A MA 46673 A MA46673 A MA 46673A MA 046673 A MA046673 A MA 046673A MA 46673 A MA46673 A MA 46673A MA 46673 A MA46673 A MA 46673A
- Authority
- MA
- Morocco
- Prior art keywords
- dkk
- catenin
- biomarker
- antibody
- beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662413198P | 2016-10-26 | 2016-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46673A true MA46673A (fr) | 2019-09-04 |
Family
ID=60570180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046673A MA46673A (fr) | 2016-10-26 | 2017-10-26 | Utilisation de la bêta-caténine en tant que biomarqueur pour traiter des cancers à l'aide d'un anticorps anti-dkk-1 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11267876B2 (https=) |
| EP (1) | EP3532099A1 (https=) |
| JP (2) | JP7374765B2 (https=) |
| KR (1) | KR102701695B1 (https=) |
| CN (1) | CN110114087A (https=) |
| AU (1) | AU2017347822B2 (https=) |
| BR (1) | BR112019008279A2 (https=) |
| CA (1) | CA3041325A1 (https=) |
| IL (1) | IL266199B2 (https=) |
| MA (1) | MA46673A (https=) |
| MX (1) | MX2019004940A (https=) |
| RU (1) | RU2019115946A (https=) |
| SG (1) | SG11201903602RA (https=) |
| WO (1) | WO2018081437A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3041325A1 (en) | 2016-10-26 | 2018-05-03 | Leap Therapeutics, Inc. | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |
| CA3128526A1 (en) | 2019-02-01 | 2020-08-06 | Board Of Regents, The University Of Texas System | Monoclonal antibodies against mhc-bound human dickkopf-1 peptides and uses thereof |
| CA3151228A1 (en) * | 2019-09-19 | 2021-03-25 | Leap Therapeutics, Inc. | Use of dkk-1 inhibitors for treating cancer |
| EP4061419A1 (en) * | 2019-11-22 | 2022-09-28 | Leap Therapeutics, Inc. | Methods of treating cancer using dkk-1-inhibitors |
| WO2023143444A1 (zh) | 2022-01-28 | 2023-08-03 | 上海君实生物医药科技股份有限公司 | 抗dkk1抗体、其药物组合物及用途 |
| US20250222062A1 (en) * | 2022-03-24 | 2025-07-10 | The Translational Genomics Research Institute | Peptide inhibitors targeting the tbl1-beta-catenin complex |
| CN116350758B (zh) * | 2023-03-16 | 2024-08-06 | 郑州大学 | 肿瘤共享新抗原表位肽或其编码核酸在制备药物中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7446181B2 (en) | 1998-01-15 | 2008-11-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind human Dickkopf-1 proteins |
| AR060017A1 (es) | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
| CA2677356A1 (en) | 2007-02-08 | 2008-08-14 | Zhiqiang An | Antibodies specific for dkk-1 |
| WO2009028158A1 (en) | 2007-08-24 | 2009-03-05 | Oncotherapy Science, Inc. | Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker |
| AR075989A1 (es) | 2009-04-10 | 2011-05-11 | Lilly Co Eli | Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria |
| EP2427490A1 (en) | 2009-05-07 | 2012-03-14 | Novartis AG | Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both |
| CA2783665A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| WO2012103787A1 (en) * | 2011-02-01 | 2012-08-09 | The University Of Hongkong | Use of anti-dkk1 monoclonal antibody for treatment of liver cancer |
| JP6465790B2 (ja) * | 2013-02-27 | 2019-02-06 | 第一三共株式会社 | Ｍａｐｋシグナル伝達経路を阻害する化合物に対する応答性を予測する方法 |
| CA2931975A1 (en) | 2013-12-02 | 2015-06-11 | Oncomed Pharmaceuticals, Inc. | Identification of predictive biomarkers associated with wnt pathway inhibitors |
| CA3041325A1 (en) | 2016-10-26 | 2018-05-03 | Leap Therapeutics, Inc. | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |
| CA3151228A1 (en) | 2019-09-19 | 2021-03-25 | Leap Therapeutics, Inc. | Use of dkk-1 inhibitors for treating cancer |
| EP4061419A1 (en) | 2019-11-22 | 2022-09-28 | Leap Therapeutics, Inc. | Methods of treating cancer using dkk-1-inhibitors |
| WO2023039249A1 (en) | 2021-09-10 | 2023-03-16 | Leap Therapeutics, Inc. | Combination therapy |
| IL318268A (en) | 2022-07-12 | 2025-03-01 | Leap Therapeutics Inc | Combined treatment |
-
2017
- 2017-10-26 CA CA3041325A patent/CA3041325A1/en active Pending
- 2017-10-26 MX MX2019004940A patent/MX2019004940A/es unknown
- 2017-10-26 JP JP2019522823A patent/JP7374765B2/ja active Active
- 2017-10-26 BR BR112019008279-4A patent/BR112019008279A2/pt active Search and Examination
- 2017-10-26 WO PCT/US2017/058555 patent/WO2018081437A1/en not_active Ceased
- 2017-10-26 CN CN201780071597.0A patent/CN110114087A/zh active Pending
- 2017-10-26 KR KR1020197014600A patent/KR102701695B1/ko active Active
- 2017-10-26 IL IL266199A patent/IL266199B2/en unknown
- 2017-10-26 MA MA046673A patent/MA46673A/fr unknown
- 2017-10-26 SG SG11201903602RA patent/SG11201903602RA/en unknown
- 2017-10-26 EP EP17808633.6A patent/EP3532099A1/en active Pending
- 2017-10-26 AU AU2017347822A patent/AU2017347822B2/en active Active
- 2017-10-26 US US16/345,191 patent/US11267876B2/en active Active
- 2017-10-26 RU RU2019115946A patent/RU2019115946A/ru unknown
-
2022
- 2022-01-28 US US17/587,708 patent/US12319730B2/en active Active
-
2023
- 2023-07-26 JP JP2023121862A patent/JP2023133432A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11267876B2 (en) | 2022-03-08 |
| CA3041325A1 (en) | 2018-05-03 |
| MX2019004940A (es) | 2019-09-26 |
| SG11201903602RA (en) | 2019-05-30 |
| BR112019008279A2 (pt) | 2019-07-09 |
| AU2017347822A1 (en) | 2019-05-09 |
| IL266199B1 (en) | 2024-10-01 |
| IL266199B2 (en) | 2025-02-01 |
| RU2019115946A (ru) | 2020-11-27 |
| AU2017347822B2 (en) | 2025-01-16 |
| US20190284264A1 (en) | 2019-09-19 |
| CN110114087A (zh) | 2019-08-09 |
| KR20190085935A (ko) | 2019-07-19 |
| US12319730B2 (en) | 2025-06-03 |
| KR102701695B1 (ko) | 2024-08-30 |
| US20220289831A1 (en) | 2022-09-15 |
| JP7374765B2 (ja) | 2023-11-07 |
| JP2019533693A (ja) | 2019-11-21 |
| JP2023133432A (ja) | 2023-09-22 |
| EP3532099A1 (en) | 2019-09-04 |
| IL266199A (en) | 2019-06-30 |
| RU2019115946A3 (https=) | 2021-01-26 |
| WO2018081437A1 (en) | 2018-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46673A (fr) | Utilisation de la bêta-caténine en tant que biomarqueur pour traiter des cancers à l'aide d'un anticorps anti-dkk-1 | |
| EP3903817A4 (en) | NOVEL ANTI-CRR8 ANTIBODY | |
| MA53338A (fr) | Dosages pour détecter la neurodégénérescence | |
| MA48604A (fr) | Anticorps anti-tim-3 pour une combinaison avec des anticorps anti-pd-1 | |
| MA46952A (fr) | Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet | |
| HUE041669T2 (hu) | Farmakon elleni ellenanyag jelenlétének vagy mennyiségének kimutatására szolgáló assay-k | |
| EP3359573A4 (en) | MARKING OF ANTIBODIES | |
| MA46057A (fr) | Anticorps anti-ctla4 | |
| MA40682A (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
| EP3507307A4 (en) | BISPECIFIC ANTIBODIES | |
| MA44236A (fr) | Anticorps anti-tgfbêta 2 | |
| EP3717916C0 (en) | TARGET INTERFERENCE SUPPRESSION ANTI-DRUG ANTIBODY ASSAY | |
| MA45687A (fr) | 99mtc-edda/hynic-ipsma à utiliser en tant que radiopharmaceutique pour détecter la surexpression de l'antigène membranaire spécifique de la prostate | |
| MA49377A (fr) | Utilisation d'anticorps anti-cd70 argx-110 pour traiter la leucémie myéloïde aiguë | |
| EP3376229A4 (en) | BIOMARKERS FOR THE DIAGNOSIS OF DEPRESSIONS AND THE USE OF THE BIOMARKER | |
| EP3384035A4 (en) | ASSAYS FOR THE DETECTION OF AAV-NEUTRALIZING ANTIBODIES | |
| EP3484919A4 (en) | ANTIBODIES AGAINST AMYLOID BETA | |
| MA52152A (fr) | Anticorps | |
| EP3399992A4 (en) | SELF-NETWORKING ANTIBODIES | |
| EP3493819A4 (en) | Keratin 17 as an organic marker for bladder cancer | |
| EP3397262A4 (en) | COMBINATION OF AN HDAC INHIBITOR AND ANTI-PD-L1 ANTIBODY FOR THE TREATMENT OF EGG CANCER | |
| FR3047674B1 (fr) | Utilisation d'amines alkoxylees en tant qu'agents collecteurs pour l'enrichissement de minerai | |
| EP3397360A4 (en) | PEDAL ARRANGEMENT FOR EXERCISE MACHINE | |
| EP3582683A4 (en) | SEROLOGICAL TEST FOR SILENT BRAIN ISEMIA | |
| EP3341414A4 (en) | ANTIBODIES AND TESTS FOR DETECTION OF CD37 |